Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Nov 12;8(21):5539-5541.
doi: 10.1182/bloodadvances.2024013600.

Comparison of patients with myeloma receiving zoledronic acid vs denosumab: a nationwide retrospective cohort study

Ghulam Rehman Mohyuddin  1 , Jenny S Guadamuz  2   3 , Mustafa S Ascha  2 , Brian C-H Chiu  4 , Pritesh R Patel  5 , Karen Sweiss  6 , Rebecca Rohrer  2 , Douglas Sborov  1 , Gregory S Calip  2   7
Affiliations

Comparison of patients with myeloma receiving zoledronic acid vs denosumab: a nationwide retrospective cohort study

Ghulam Rehman Mohyuddin et al. Blood Adv. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

Conflict-of-interest disclosure: G.R.M. reports royalties from MashupMD for writing (the institution has received funding from Janssen for site principal investigator role). G.S.C., J.S.G., M.S.A., and R.R. report employment with Flatiron at the time of writing; and equity holding in Roche, a publicly traded company, at the time of writing. D.S. reports research funding from Gilead; consultancy and research funding from Arcell, Pfizer, Bioline, Sanofi, Janssen, and GlaxoSmithKline; consultancy for Bristol Myers Squibb; and AbbVie; research funding from Amgen, Cantex, and Rochex. P.R.P. reports employment with Exelixis. The remaining authors declare no competing financial interests.

Figures

Figure 1.
Figure 1.
rwOS and rwPFS between patients treated with bisphosphonates vs those treated with denosumab, with time expressed from month since starting treatment. rw, real-world.
See this image and copyright information in PMC

References

    1. Sonneveld P, Dimopoulos MA, Boccadoro M, et al. Daratumumab, bortezomib, lenalidomide, and dexamethasone for multiple myeloma. N Engl J Med. 2024;390(4):301–313. - PubMed
    1. Zamagni E, Cavo M, Fakhri B, Vij R, Roodman D. Bones in multiple myeloma: imaging and therapy. Am Soc Clin Oncol Educ Book. 2018;38:638–646. - PubMed
    1. Terpos E, Zamagni E, Lentzsch S, et al. Treatment of multiple myeloma-related bone disease: recommendations from the Bone Working Group of the International Myeloma Working Group. Lancet Oncol. 2021;22(3):e119–e130. - PubMed
    1. Morgan GJ, Davies FE, Gregory WM, et al. First-line treatment with zoledronic acid as compared with clodronic acid in multiple myeloma (MRC Myeloma IX): a randomised controlled trial. Lancet. 2010;376(9757):1989–1999. - PMC - PubMed
    1. Goldstein DA. Denosumab for bone lesions in multiple myeloma - what is its value? Haematologica. 2018;103(5):753–754. - PMC - PubMed